Gillian M. Cannon recently transitioned from a very successful career spanning 30 years in the pharmaceutical industry to set up Castle Biotech LLC, a US based business that will develop and commercialise new technologies relating to the use of Nitric Oxide based chemistries to improve cardiovascular and inflammatory function.
Gillian was most recently the President of North American Operations for UCB, a Belgium based pharmaceutical company, where she was responsible for providing leadership and strategic direction to all aspects of the organization’s operations in the U.S., Mexico and Canada.
Prior to joining UCB, Gillian was Senior Vice President of Customer Strategy and Analytics at Otsuka Pharmaceuticals. In her 30 years of experience in the pharmaceutical industry, Gillian has worked in global, U.S. and European roles. She has held senior leadership positions at Merck & Co Inc., Otsuka Pharmaceuticals and UCB across a broad range of disciplines including Market Access, Outcomes Research, Sales Leadership, Marketing, Business Development and Strategic Planning.
In addition to her commercial experience, Gillian has a demonstrated track record of successfully implementing new business initiatives. She was responsible for creating the commercial organization to develop and commercialize Biosimilars at Merck (Merck BioVentures). She also led two innovation partnerships at Otsuka – Otsuka Digital Health, a partnership with IBM, to develop effective care coordination in mental health, and MIND, a collaboration with Proteus Digital Health to develop a “smart pill” for patients with schizophrenia.
Gillian is a lecturer in Pharmaceutical Drug Development at Drexel University. She holds an undergraduate degree in Biochemistry from the University of Edinburgh and a PhD in Health Administration from Temple University